Rising Global Disease Burden and Increasing Demand for Innovative Treatments to Bolster Pharmaceuticals Market Growth During 2024-2031

According to our new research study on "Pharmaceuticals Market Forecast to 2031 - Global Analysis - by Molecule Type, Indication, Product, Type, and Distribution Channel" the market is expected to grow from US$ 2,840.30 Bn by 2031 from US$ 1,757.78 Bn in 2024; it is estimated to grow at a CAGR of 7.1% during 2024-2031. The report highlights trends prevailing in the market, and drivers and restraints pertaining to the market growth.

As the pharmaceutical industry evolves, global medicine use has significantly increased due to improved access to medications. Medicine use, measured in defined daily doses, has increased by 36% over the past decade due to greater availability and adoption of treatments. However, growth is expected to slow through 2027, with total medicine use reaching 3.4 trillion doses-an 8% increase from 2022 levels. The highest volume growth is anticipated in Latin America, Asia, and Africa, largely due to a combination of population expansion and improved healthcare accessibility, while North America and Europe will see very low growth. Pharmaceutical spending also reflects these trends. The global medicine market is expected to grow at a compound annual growth rate (CAGR) of 3-6% through 2027, reaching US$ 1.9 trillion. The growth trajectory varies by region-developed economies will maintain steady growth rates as new products offset losses from patent expiries, while Latin America, Eastern Europe, and parts of Asia will see robust expansion due to volume increases and higher adoption of innovative medicines. While new brand spending in the US will surpass the last five years, it will constitute a smaller share of total spending.

The role of Italy as a key player in the pharmaceutical industry further exemplifies the shift toward international markets.

In 2023-24, the global pharmaceutical market remained a cornerstone of healthcare accessibility, with total exports valued at US$ 834.80 billion, despite a US$ 9.70 billion decline from the previous year. As demand for essential medicines grows, both established and emerging markets play a pivotal role in global supply chains. Germany led pharmaceutical exports with US$ 119.85 billion (14.4% of total exports), with the USA (US$ 27.40 billion, 22.9% share) as its top destination, showcasing its dominance in high-quality drug manufacturing. Switzerland followed with US$99.08 billion (11.9%), primarily exporting to the USA (US$ 30.72 billion, 31% share), reinforcing its stronghold in innovative therapies. The United States, ranked third with US$ 90.30 billion (10.8%), was a key supplier to China (US$ 9.89 billion, 11%), highlighting shifting global trade dynamics. Belgium (US$ 82.52 billion, 9.9%) and Ireland (US$ 71.56 billion, 8.6%) remained major players, though both experienced declines of 20% and 5%, respectively, emphasizing the need for resilient market strategies.

Beyond established economies, emerging markets are increasingly shaping global pharmaceutical trade. Italy's exports reached US$50.32 billion (6%), growing 6% YoY, with the USA (US$8.43 billion, 16.8%) as its primary buyer. France (US$38.01 billion, 4.6%), the Netherlands (US$34.19 billion, 4.1%), and the United Kingdom (US$27.49 billion, 3.3%) continued their expansion, with the Netherlands seeing a notable 20% increase, largely driven by demand from Germany (US$6.24 billion, 18.3%). Meanwhile, Spain (US$21.86 billion, 2.6%), despite a 22% drop, remained a critical supplier to Belgium.

As emerging economies strengthen their pharmaceutical capabilities, opportunities for investment, technology transfer, and regulatory harmonization are accelerating. The shifting landscape underscores the need for sustainable access strategies, ensuring that both developed and developing markets can meet rising healthcare demands efficiently.

The U.S. Inflation Reduction Act (IRA) will also influence pharmaceutical pricing and cost-sharing. However, specific impacts remain uncertain due to the lack of a baseline for implementation. As global demand continues to grow, spending on cancer treatments will reach US$ 370 billion by 2027, while neurology spending will rise due to new treatments for rare neurological disorders, Alzheimer's, and migraines. Immunology spending growth is expected to slow to 3-6% through 2027, with volume increases of 12% annually, driven by price reductions from biosimilar competition.

Overall, pharmaceutical spending and demand will continue rising, shaped by regional growth trends, increased access to medicines, expanding public-private collaborations, and ongoing innovations in specialty and biotech treatments.

Rising Global Disease Burden and Increasing Demand for Innovative Treatments Is Propelling The Growth of Pharmaceuticals Market

The pharmaceutical industry regularly grows by 6% every year, primarily due to the increasing number of people suffering from chronic and severe health conditions. The global burden of diseases such as diabetes, obesity, cancer, and Alzheimer's continues to rise at an alarming rate, fueling the need for medical advancements. There are currently 171 million diabetics worldwide, and this figure is expected to double by 2030. Obesity affects 1.4 billion people, and projections estimate that this number will reach 3.3 billion by 2030. Cancer is a major health concern, with 1 in 20 women diagnosed with breast cancer and 1 in 12 men diagnosed with cancer overall. Furthermore, 18 million people suffer from Alzheimer's, and the number is likely to increase to 35 million by 2025.

To address these growing illnesses, pharmaceutical companies are investing heavily in research and development research and development to create innovative treatments. Additionally, 700 million (US$ 757.42) is invested annually in clinical trials by pharma companies in Italy alone, rising to 1 billion (US$1.08) if medical device companies are included. This is further supported by the increasing role of public-private partnerships (PPPs), such as the collaboration between the National Institutes of Health, the U.S. FDA, 10 pharmaceutical companies, and five non-profit organizations to accelerate gene therapy development for 30 million Americans suffering from rare diseases.

The impact of COVID-19 has also significantly shaped pharmaceutical market expansion, adding an estimated US$ 500 billion in net cumulative market growth from 2020 through 2027. While all regions have exceeded first-wave vaccination rates, booster utilization remains inconsistent, creating uncertainties about the future course of the pandemic. The demand for innovative drugs will continue to surge, particularly in oncology, where spending is projected to reach US$ 370 billion by 2027-almost double the current level. Moreover, specialty medicines will represent 43% of global spending by 2027 and 56% of total spending in developed markets. Biotech medicines, including breakthrough cell and gene therapies, will account for 35% of global spending by 2027, marking a shift toward advanced biotherapeutics.

The pharmaceuticals market is segmented on the basis of molecule type, indication, product, type, distribution channel and geography. The pharmaceuticals market, based on molecule type, is segmented into small molecule, biological and biosimilar products. The small molecule segment held the largest share of the pharmaceuticals market in 2024. Indication, the market is segmented into metabolic diseases, cancer, immunology, respiratory disorder, cardiovascular disorder, neurology disorder, rare disease, others. The cancer segment held the largest share of the pharmaceuticals market in 2024. In terms of product, the pharmaceuticals market is bifurcated into branded and generic. The branded segment held a larger share of the pharmaceuticals market in 2024. Based on type, the market is segmented into prescription, OTC drugs. The prescription segment held the largest share of the pharmaceuticals market in 2024. By distribution channel, the pharmaceuticals market is divided into hospital pharmacies, retail pharmacies, online pharmacies. The hospital pharmacies segment held the largest share of the pharmaceuticals market in 2024

In terms of geography, the pharmaceuticals market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). Key factors contributing to the market growth in North America include the rising cancer incidence, increasing investments in research and development, and surging product launches. Additionally, strategic initiatives such as the development of new products, regulatory approvals, collaborations, and acquisitions are further propelling the growth of the pharmaceutical market in the region.

One of the primary market drivers is the aging population in North America. As people age, they often develop chronic diseases and conditions that require continuing pharmaceutical treatments. According to the US Census Bureau, by 2030, one in five Americans will be 65 years or older, fueling the demand for medications related to age-related conditions.

The pharmaceutical market is also driven by rapid innovations in biotechnology. The development of biologic drugs, personalized medicine, and gene therapies has revolutionized the treatment of diseases such as cancer, rare genetic disorders, and autoimmune diseases. This includes CAR-T cell therapies and monoclonal antibodies, which are gaining traction in the market.

Strong regulatory bodies such as the U.S. Food and Drug Administration (FDA) and Health Canada ensure pharmaceutical safety, efficacy, and quality. The regulatory process is rigorous, and it has also led to the consistent introduction of new drugs to the market.

The digital transformation of healthcare, including telemedicine and digital therapeutics, presents new opportunities for the market. Pharmaceutical companies can partner with digital health providers to create integrated solutions for chronic disease management, personalized treatment regimens, and remote patient monitoring.

Johnson & Johnson, Pfizer Inc, Merck & Co Inc, Eli Lilly and Co, Bristol-Myers Squibb Co, ESTEVE, UCB SA, Teva Pharmaceutical Industries Ltd, Hikma Pharmaceuticals Plc, Viatris Inc, AstraZeneca Plc, Sanofi SA, GSK PIc, F. Hoffmann-La Roche Ltd, Novartis AG, AbbVie Inc, are among the key players in the market.

Companies operating in the pharmaceuticals market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the pharmaceuticals market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.

A few of the developments made by the companies operating in pharmaceuticals market are as follows: